Veröffentlichungen 2013

Publikationen

1. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013;40(4):486-95. doi: 10.1007/s00259-012-2298-2.

2. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. Reply to Reske et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013;40(6):971-2.

3. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Giesel FL, Debus J, Haberkorn U. Comparison of PET imaging with a 68Ga-labelled PSMA-ligand and 18F-choline based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nuc Med Mol Imaging 2013; [Epub ahead of print].

4. Afshar-Oromieh A, Haberkorn U, Hadaschik B, Habl G, Eder M, Eisenhut M, Schlemmer HP, Roethke MC. PET/MRI with a (68)Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging 2013:1629-30. doi: 10.1007/s00259-013-2489-5. Epub 2013 Jul 2. No abstract available.

5. Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, Hadaschik BA, Kopp-Schneider A, Röthke M. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 2013; [Epub ahead of print].

6. Askoxylakis V, Marr A, Altmann A, Markert A, Mier W, Debus J, Huber PE, Haberkorn U. Peptide-Based Targeting of the Platelet-Derived Growth Factor Receptor Beta. Mol Imaging Biol 2013;15(2):212-21. doi: 10.1007/s11307-012-0578-7.

7. Bonaterra GA, Zügel S, Thogersen J, Walter SA, Haberkorn U, Strelau J, Kinscherf R. Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury. J Am Heart Assoc 2013;1(6):e002550. doi: 10.1161/JAHA.112.002550.

8. Bretschi M, Cheng C, Witt H, Dimitrakopoulou-Strauss A, Strauss LG, Semmler W, Baeuerle T. Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal 18F-FDG PET and gene expression analysis. J Cancer Res Clin Oncol 2013;139(4):573-83. doi: 10.1007/s00432-012-1360-6.

9. Celik B, Yalcin AD, Bisgin A, Dimitrakopoulou-Strauss A, Kargi A, Strauss LG. Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers. Med Sci Monit 2013;19:875-82. doi: 10.12659/MSM.889605.

10. Cheng C, Heiss C, Dimitrakopoulou-Strauss A, Govindarajan P, Schlewitz G, Pan L, Schnettler R, Weber K, Strauss LG. Evaluation of bone remodeling with (18)F-fluoride and correlation with the glucose metabolism measured by (18)F-FDG in lumbar spine with time in an experimental nude rat model with osteoporosis using dynamic PET-CT. Am J Nucl Med Mol Imaging 2013;3(2):118-28.

11. Cheng C, Alt V, Dimitrakopoulou-Strauss A, Pan L, Thormann U, Schnettler R, Weber K, Strauss LG. Evaluation of New Bone Formation in Normal and Osteoporotic Rats with a 3-mm Femur Defect: Functional Assessment with Dynamic PET-CT (dPET-CT) Using 2-Deoxy-2-[(18)F]Fluoro-D-glucose ( (18)F-FDG) and (18)F-Fluoride. Mol Imaging Biol 2013;15:336-344.

12. Cheng C, Alt V, Pan L, Thormann U, Schnettler R, Strauss LG, Schumacher M, Gelinsky M, Dimitrakopoulou-Strauss A. Preliminary evaluation of different biomaterials for defect healing in an experimental osteoporotic rat model with dynamic PET-CT (dPET-CT) using F-18-Sodium Fluoride (NaF).  Injury 2013; pii: S0020-1383(13)00558-5. doi: 10.1016/ j.injury.2013.11.023. [Epub ahead of print].

13. Combs SE, Welzel T, Habermehl D, Rieken S, Dittmar JO, Kessel K, Jäkel O, Haberkorn U, Debus J. Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and (68)Ga-DOTATOC-PET. Acta Oncol 2013;52:514-520.

14. Delorme S, Zechmann C, Haberkorn U. [Imaging diagnostics of hyperparathyroidism]. Radiologe 2013;53(3):261-76. doi: 10.1007/s00117-012-2458-1.

15. Dimitrakopoulou-Strauss A, Carrió I. In memoriam: Ludwig G. Strauss, MD, 1949-2013. Eur J Nucl Med Mol Imaging 2013;40(9):1299-300.

16. Dimitrakopoulou-Strauss A, Frenkel A, Epelbaum R. Reply: Understanding SUV Variability in Reference Tissue for 18F-FDG PET with a Simple Measurement Model. J Nucl Med 2013; [Epub ahead of print] No abstract available.

17. Eder M, Eisenhut M, Babich J, Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging 2013;40:819-823.

18. Eder M, Löhr T, Bauder-Wüst U, Reber M, Mier W, Schäfer M, Haberkorn U, Eisenhut M. Pharmacokinetic Properties of Peptidic Radiopharmaceuticals: Reduced Uptake of (EH)3-Conjugates in Important Organs. J Nucl Med 2013;54:1327-1330.

19. Epelbaum R, Frenkel A, Haddad R, Sikorski N, Strauss LG, Israel O, Dimitrakopoulou-Strauss A. Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic FDG-PET/CT. J Nucl Med 2013;54(1):12-8. doi: 10.2967/jnumed.112.107466.

20. Flechsig P, Kratochwil C, Schwartz LH, Rath D, Moltz J, Antoch G, Heussel C-P, Rieser M, Warth A, Zabeck H, Kauczor H-U, Haberkorn U, Giesel FL Quantitative Volumetric CT-Histogram analysis in N-staging of FDG-equivocal patients with lung cancer. J Nucl Med, in press.

21. Fortuin A, Rooij MD, Zamecnik P, Haberkorn U, Barentsz J. Molecular and functional imaging for detection of lymph node metastases in prostate cancer. Int J Mol Sci 2013;14(7):13842-57. doi: 10.3390/ijms140713842.

22. Giesel F, Stefanova M, Schwartz LH, Afshar-Oromieh A, Eisenhut M, Haberkorn U, Kratochwil C. Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue. Q J Nucl Med Mol Imaging 2013;57(2):171-176.

23. Giesel F, Mavriopoulou E, Rath D, Afshar-Oromieh A, Haufe S, Apostolopoulos D, Mier W, Haberkorn U, Kratochwil C. Comparison of 68Ga-DOTATOC biodistribution in patients with and without splenectomy. J Nucl Med 2013; 54 (Supplement 2):1906 (in print).

24. Giesel FL, Flechsig P, Kuder T, Schwartz LH, Wulfert S, Zechmann CM, Bruchertseifer F, Haberkorn U, Kratochwil C.  Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial (177)Lu/(90)Y-DOTATOC and (213)Bi-DOTATOC radiopeptide therapy. Exp Oncol 2013;35(2):122-6.

25. Grünberg J, Jeger S, Sarko D, Dennler P, Zimmermann K, Mier W, Schibli R. DOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl. PLoS One 2013;8(4):e60350. doi: 10.1371/journal.pone.0060350.

26. Hill A, Breyer S, Geissler S, Mier W, Haberkorn U, Weigandt M, Mäder K. How do in-vitro release profiles of nanosuspensions from Alzet® pumps correspond to the in-vivo situation? A case study on radiolabeled fenofibrate. J Control Release 2013;168(1):77-87. doi: 10.1016/j.jconrel.2013.03.005.

27. Jamous M, Haberkorn U, Mier W. Synthesis of Peptide Radiopharmaceuticals for the Therapy and Diagnosis of Tumor Diseases. Molecules 2013;18(3):3379-3409.

28. Kasper B, Dimitrakopoulou-Strauss A, Pilz LR, Strauss LG, Sachpekidis C, Hohenberger P. Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib. Biomed Res Int 2013;2013:389672. doi: 10.1155/2013/389672.

29. Kratochwil C, Combs SE, Leotta K, Afshar-Oromieh A, Rieken S, Debus J. Haberkorn U, Giesel FL. Intra-individual comparison of 18F-FETand 18F-DOPA in PET imaging of recurrent brain tumors. Neuro-Oncology 2013; 0, 1–7, doi:10.1093/neuonc/not199.

30. Kristen AV, Haufe S, Schonland SO, Hegenbart U, Schnabel PA, Röcken C, Hardt S, Lohse P, Ho AD, Haberkorn U, Dengler TJ, Altland K, Katus HA. Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol 2013;164(2):179-84. doi: 10.1016/j.ijcard.2011. 06.123.

31. Küntzelmann A, Guenther T, Haberkorn U, Essig M, Giesel F, Henze R, Schroeter ML, Schröder J, Schönknecht P. Impaired cerebral glucose metabolism in prodromal Alzheimer's disease differs by regional intensity normalization. Neurosci Lett 2013;534:12.

32. Liu Y, Baeuerle T, Pan L, Dimitrakopoulou-Strauss A, Strauss LG, Heiss C, Schnettler R, Semmler W, Cao L. Calibration of cone beam CT using relative attenuation ratio for quantitative assessment of bone density: a small animal study. Int J Comput Assist Radiol Surg 2013;8(5):733-739. doi: 10.1007/s11548-012-0803-5. 

33. López-Benítez R, Hallscheidt P, Kratochwil C, Ernst C, Kara L, Rusch O, Vock P, Kettenbach J. Protective Embolization of the Gastroduodenal Artery with a One-HydroCoil Technique in Radioembolization Procedures. Cardiovasc Intervent Radiol 2013;36(1):105-10. doi: 10.1007/s00270-012-0361-9.

34. Marr A, Nissen F, Maisch D, Altmann A, Rana S, Debus P, Huber PE, Haberkorn U, Askoxylakis V. Peptide arrays for development of PDGFRß affine molecules. Mol Imaging Biol 2013;15(4):391-400. doi: 10.1007/s11307-013-0616-0.

35. Meier A, Mehrle S, Weiss TS, Mier W, Urban S. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatolog  2013;58(1):31-42. doi: 10.1002/hep.26181.

36. Mier W, Krämer S, Zitzmann S, Altmann A, Leotta K, Schierbaum U, Schnölzer M, Eisenhut M, Haberkorn U. PEGylation enables the specific tumor accumulation of a peptide identified by phage display. Org Biomol Chem 2013;11(16):2706-11.

37. Mier W, Kratochwil C, Hassel JC, Giesel FL, Beijer B, Babich JW, Friebe M, Eisenhut M, Enk A, Haberkorn U. RADIONUCLIDE THERAPY of patients with metastasized melanoma with the melanin-binding benzamide iodine-131-BA52. J Nucl Med 2013; [Epub ahead of print].

38. Mier W, Babich J, Haberkorn U. Is nano too big? Eur J Nucl Med Mol Imaging 2013: [Epub ahead of print] No abstract available.

39. Miller T, Breyer S, van Colen G, Mier W, Haberkorn U, Geissler S, Voss S, Weigandt M, Goepferich A. Premature drug release of polymeric micelles and its effects on tumor targeting. Int J Pharm 2013;445(1-2):117-124. doi: 10.1016/j.ijpharm.2013.01.059.

40. Müller T, Mehrle S, Schieck A, Haberkorn U, Urban S, Mier W. Liver Imaging with a Novel Hepatitis B Surface Protein Derived SPECT-Tracer. Mol Pharm 2013;10(6):2230-6. doi: 10.1021/mp400038r.

41. Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, Lohmann V, Mier W, Mehrle S, Urban S. Cyclosporin A inhibits Hepatitis B and Hepatitis D Virus entry by Cyclophilin-independent interference with the NTCP receptor. J Hepatol 2013;doi:pii: S0168-8278(13)00824-6. 10.1016/j.jhep.2013.11.022. [Epub ahead of print].

42. Raake PW, Schlegel P, Ksienzyk J, Reinkober J, Barthelmes J, Schinkel S, Pleger S, Mier W, Haberkorn U, Koch WJ, Katus HA, Most P, Müller OJ.AAV6. ßARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 2013;34:1437-1447.

43. Rana S, Nissen F, Lindner T, Altmann A, Mier W, Debus J, Haberkorn U, Askoxylakis V. Screening of a Novel Peptide Targeting the Proteoglycan-Like Region of Human Carbonic Anhydrase IX. Mol Imaging 2013;12(8):497-508.

44. Rengier F, Häfner MF, Unterhinninghofen R, Kirsch J, Kauczor HU, Giesel FL. Integration of interactive three-dimensional image post-processing software into undergraduate radiology education effectively improves diagnostic skills and visual-spatial ability. Eur J Radiol 2013;82(8):1366-1371. doi: 10.1016/ j.ejrad.2013. 01.010.

45. Rieken S, Habermehl D, Giesel FL, Hoffmann C, Burger U, Rief H, Welzel T, Haberkorn U, Debus J, Combs SE. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy. Radiother Oncol 2013;109(3):487-92. doi: 10.1016/j.radonc.2013.06.043.

46. Roethke MC, Kuru TH, Afshar-Oromieh A, Schlemmer HP, Hadaschik BA, Fenchel M. Hybrid Positron Emission Tomography-Magnetic Resonance Imaging with Gallium 68 Prostate-specific Membrane Antigen Tracer: A Next Step for Imaging of Recurrent Prostate Cancer-Preliminary Results. Eur Urol 2013;64(5):862-4. doi:pii: S0302-2838(13)00824-5. 10.1016/j.eururo.2013.08.003.

47. Röthke MC, Afshar-Oromieh A, Schlemmer HP. [Potential of PET/MRI for diagnosis of prostate cancer]. Radiologe 2013;53(8):676-81. doi: 10.1007/s00117-013-2499-0.

48. Sachpekidis C, Roumia S, Schwarzbach M, Dimitrakopoulou-Strauss A. Dynamic (18)F-fluorodeoxyglucose positron emission tomography/CT in hibernoma: Enhanced tracer uptake mimicking liposarcoma. World J Radiol 2013;5(12):498-502. doi: 10.4329/wjr.v5.i12.498.

49. Schieck A, Schulze A, Gähler C, Müller T, Haberkorn U, Alexandrov A, Urban S, Mier W. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. Hepatology 2013;;58(1):43-53. doi: 10.1002/hep.26211.

50. Strauss LG, Koczan D, Klippel S, Pan L, Willis S, Sachpekidis C, Dimitrakopoulou-Strauss A. Dynamic PET with 18F-Deoxyglucose (FDG) and quantitative assessment with a two-tissue compartment model reflect the activity of glucose transporters and hexokinases in patients with colorectal tumors. Am J Nucl Med Mol Imaging 2013;3(5):417-424.

51. Takesh M, Adams S. Imaging Comparison between (18) F-FDG-PET/CT and (18) F-Flouroethyl Choline PET/CT in Rare Case of Thymus Carcinoma Exhibiting a Positive Choline Uptake. Case Rep Oncol Med 2013;2013:464396. doi: 10.1155/2013/464396.

52. Weber MA, Bender K, von Gall C, Stange A, Grünberg K, Ott K, Haberkorn U, Kauczor HU, Zechmann C. Assessment of diffusion-weighted MRI and 18F-fluorodeoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction. J Gastrointestin Liver Dis 2013;22:45-52.

53.  Yalcin AD, Cilli A, Bisgin A, Strauss LG, Herth F. Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels. Expert Opin Biol Ther 2013;13(9):1335-41. doi: 10.1517/14712598.2013.819338. 

54. Yalcin AD, Karakas AA, Soykam G, Gorczynski RM, Sezer C, Bisgin A, Strauss LG. A case of toxic epidermal necrolysis with diverse etiologies: successful treatment with intravenous immunoglobulin and pulse prednisolone and effects on sTRAIL and sCD200 levels. Clin Lab 2013;59(5-6):681-5. 

55. Yalcin AD, Uçar S, Gumuslu S, Strauss LG. Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter's syndrome: 36 months follow-up. Immunopharmacol Immunotoxicol 2013;35(4):524-7.

56. Zoller F, Riss PJ, Montforts FP, Kelleher DK, Eppard E, Rösch F. Radiolabelling and preliminary evaluation of 68Ga-tetrapyrrole derivatives as potential tracers for PET. Nucl Med Biol 2013;40(2):280-8. doi: 10.1016/j.nucmedbio.2012.11.006.

57. Zoller F, Markert A, Barthe P, Hebling U, Altmann A, Lindner T, Mier W, Haberkorn U. A Disulfide-Constrained Miniprotein with Striking Tumor-Binding Specificity Developed by Ribosome display. Angew Chem Int Ed 2013;52:11760-11764.

Buchbeiträge

1. Giesel FL, Kratochwil C. Imaging Peptides, Proteins, and Antibody delivery. In: Li C, Tian M. (eds), Drug Delivery Applications of Noninvasive Imaging: Validation from Biodistribution to Sites of Action. Wiley-Blackwell John Wiley & Sons Inc 2013, pp 192-198. ISBN 978-1-118-35684-5.

2. Mehndiratta A, Tee KT, Payne SJ, Chappell MA, Giesel FL. An Introduction to Brain Tumor Imaging. In: Hayat MH (ed), Tumors of the Central Nervous System. Springer-Verlag 2013, in print.

3. Mehndiratta A, Prabu A, Kashyap R, Chaurasia A, Giesel FL. Acute Nutritional Emergencies. In: Goel A, Joshi R, Jain AP (eds.), ICU Manual. Paras Medical Publisher 2013, pp 223-225. ISBN 978-81-8191-374-6.

4. Mehndiratta A, Anandaraj P, Zechmann C, Giesel FL. Nuclear Medicine. An overview of Imaging Techniques, Clinical Applications and Trials. In: Miller CG, Krasnow J, Schwartz LH. (eds), Medical Imaging in Clinical Trials. Springer Verlag 2013, in print.

5. von Tengg-Kobligk H, Mehndiratta A, Giesel FL. Contrast Agents in Radiology. In: Miller CG, Krasnow J, Schwartz LH. (eds.), Medical Imaging in Clinical Trials. Springer Verlag 2013, in print.

nach oben
powered by webEdition CMS